Researchers present results from pivotal cancer trials, including an ADC-Keytruda combination, at the European Society for Medical Oncology Congress on Oct. 22 (Kyle LaHucik for Endpoints News)

October 23, 2023 08:32 AM EDTUpdated 10:59 AM

R&D

In Focus

You get an ADC, you get an ADC: Pharmas bite on oncology’s buzziest class

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

MADRID — When Daiichi Sankyo scientists pushed forward with antibody-drug conjugate research nearly a decade ago, the program had a lot of naysayers, even inside the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

You get an ADC, you get an ADC: Pharmas bite on oncology’s buzziest class

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Updated: Sage reports Phase 2 failure in Huntington's disease, ends drug's development

Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy

Pfizer taps oncology head Boshoff as Dolsten's chief scientific officer successor

Exclusive: Former Pfizer commercial chief Angela Hwang to join Flagship

GSK plots regulatory filings for PBC itch after positive Phase 3 readout

Are programs with compounded GLP-1s safe for your population?

You get an ADC, you get an ADC: Phar­mas bite on on­col­o­gy’s buzzi­est class

News Reporter

Senior Reporter

Sign up to read this article for free.

You get an ADC, you get an ADC: Pharmas bite on oncology’s buzziest class